$AEON News
Last published 3h ago
- 3h agoAEONAEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire- Received FDA Type 2b feedback providing greater clarity on AEON's integrated biosimilar development strategy combining comparative analytical assessment, human pharmacodynamic studies, and a substantial body of existing comparative clinical evidence -
- 1w agoAEONAEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450GlobeNewswireSubmission advances ABP-450 biosimilar development program following recent FDA Type 2b meeting
- 1w agoAEONAEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450GlobeNewswireSubmission advances ABP-450 biosimilar development program following recent FDA Type 2b meeting Planned CMAP study designed to generate clinical evidence comparing the neuromuscular activity of ABP-450 and BOTOX®;
- 1mo agoAEONAEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711GlobeNewswireALISO VIEJO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX®
- 2mo agoAEONAEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX®GlobeNewswireABP-450 and BOTOX® demonstrated comparable rates of potency loss under thermal stress and similar site-specific oxidation patterns across methionine sites evaluated Results provide additional analytical evidence
- 2mo agoAEONAEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) ConferenceGlobeNewswireALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX®
- 2mo agoAEONAEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory OfficerGlobeNewswire- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for
- 2mo agoAEONAEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®GlobeNewswire- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed - Preliminary
- 3mo agoAEONAEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - Upfront
- 3mo agoAEONAEON Biopharma Regains Compliance with NYSE American Continued Listing StandardsGlobeNewswireALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX®
- 4mo agoAEONAEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future FundingGlobeNewswireIRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX®
- 5mo agoAEONAEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache SocietyGlobeNewswireIRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for
- 6mo agoAEONAEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire- Reported positive FDA Type 2a meeting supporting ABP-450's comparative analytical strategy under the 351(k) regulatory pathway - - Strengthened balance sheet through financing transactions and Daewoong note
- 6mo agoAEONAEON Biopharma Sets Annual Shareholder MeetingGlobeNewswire- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company
- 7mo agoAEONAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711GlobeNewswireIRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX®
- 7mo agoAEONAEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing StandardsGlobeNewswireIRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX®
- 7mo agoAEONAEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar ProgramGlobeNewswire– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® – – Reported positive FDA BPD Type 2a meeting, with
- 7mo agoAEONAEON Biopharma Announces FDA Feedback Following BPD Type 2a Meeting for the ABP-450 Biosimilar ProgramGlobeNewswireFDA provided constructive feedback on Company's analytical similarity strategy under the 351(k) biosimilar pathway Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the
- 8mo agoAEONAEON Biopharma Appoints John Bencich as Chief Financial OfficerGlobeNewswireIRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX®
- 8mo agoAEONAEON Biopharma Abstract Accepted for Presentation at 2026 American Academy of Neurology (AAN) Annual MeetingGlobeNewswireIRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX®
- 9mo agoAEONAEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November TransactionsGlobeNewswire- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the
- 11mo agoAEONAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711GlobeNewswireIRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450
- 11mo agoAEONAEON Biopharma Announces Execution of Exchange Agreement with DaewoongGlobeNewswire- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8
- 12mo agoAEONAEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting SchedulingGlobeNewswire- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the
- 1y agoAEONAEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued GrowthGlobeNewswire– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly
- 1y agoAEONAEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis DataGlobeNewswire- 100% match of visible amino acid sequence confirmed between ABP-450 and BOTOX® - - Functional assays demonstrate strong similarity in potency and composition, with directionally consistent enzymatic activity
- 1y agoAEONAEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible NotesGlobeNewswire- Combined transactions will strengthen balance sheet and reduce outstanding debt by more than 90% - - $6 million PIPE financing with potential for over $7 million of additional capital via cash-exercise warrants - -
- 1y agoAEONAEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19GlobeNewswire- Meeting date aligns with prior guidance - - FDA to review AEON's analytical development plan and initial data - IRVINE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company")
- 1y agoAEONAEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q'25 – – Type 2a meeting with the FDA anticipated in 4Q'25– – Cash runway
- 1y agoAEONAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711GlobeNewswireIRVINE, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment
- 1y agoAEONAEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025GlobeNewswireIRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment
- 1y agoAEONAEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for
- 1y agoAEONAEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing ComplianceGlobeNewswireIRVINE, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the
- 1y agoAEONAEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711GlobeNewswireIRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the
- 1y agoAEONAEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive OfficerGlobeNewswireIRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the
- 1y agoAEONAEON Biopharma Announces CEO TransitionGlobeNewswire– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27,
- 1y agoAEONAEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswire– Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for
- 1y agoAEONAEON Biopharma, Inc. to Participate in the Leerink Global Healthcare ConferenceGlobeNewswireIRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE:AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar
- 1y agoAEONAEON Biopharma, Inc. Announces Reverse Stock SplitGlobeNewswireIRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE:AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar
- 1y agoAEONAEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing StandardsGlobeNewswireIRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE:AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar
- 1y agoAEONAEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public OfferingGlobeNewswireIRVINE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE:AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar
- 1y agoAEONAEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public OfferingGlobeNewswireIRVINE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE:AEON) (the "Company"), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar
- 1y agoAEONAEON Biopharma, Inc. Announces Launch of Proposed Public OfferingGlobeNewswireIRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k)
- 2y agoAEONAEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire– Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as
- 2y agoAEONAEON Biopharma Announces Positive Outcome from FDA Biosimilar Advisory MeetingGlobeNewswire– Company is aligned with the FDA on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – –
- 2y agoAEONAEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024GlobeNewswireIRVINE, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment
- 2y agoAEONAEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire– Progressing plans to develop ABP-450 (prabotulinumtoxinA) injection as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – – Scheduled to hold a biosimilar initial advisory meeting with
- 2y agoAEONAEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450GlobeNewswire– Plan to move ahead with a head-to-head comparison to BOTOX® in a cervical dystonia Phase 3 study via the 351(k) pathway following an in-person FDA meeting scheduled for Q3 2024 – IRVINE, Calif., July 09, 2024
- 2y agoAEONAEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction PlanGlobeNewswireIRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for
- 2y agoAEONAEON Biopharma Reports First Quarter 2024 Financial ResultsGlobeNewswire– Ongoing analysis of interim data from the Phase 2 study of ABP-450 in chronic migraine, which did not achieve its primary or secondary endpoints – – Evaluating next-steps across the Company's late-stage clinical